Experienced in Prostate Cancer

Susanne Osanto

Leiden, ZH, NL 
Experienced in Prostate Cancer
Leiden, ZH, NL 
OverviewLocationsClinical Research

Overview

Susanne Osanto practices in Leiden, Netherlands. Ms. Osanto is rated as an Experienced expert by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Testicular Cancer, Renal Cell Carcinoma (RCC), Prostate Cancer, Prostatectomy, and Orchiectomy.

Her clinical research consists of co-authoring 62 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 15 articles and participated in 2 clinical trials in the study of Prostate Cancer.

Gender
Female

Locations

Leiden, ZH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide in Chemo-Naïve Patients With Progressive Prostate Cancer Who Have Failed Androgen Deprivation Therapy (Castration-resistant Prostate Cancer Patients)
A Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide in Chemo-Naïve Patients With Progressive Prostate Cancer Who Have Failed Androgen Deprivation Therapy (Castration-resistant Prostate Cancer Patients)
Enrollment Status: Completed
Publish Date: April 14, 2022
Intervention Type: Drug, Device
Study Phase: Phase 2
An Exploratory Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor (AR)-Directed Therapy in Hormono-Sensitive Patients With Metastatic Prostate Cancer (Hormono-sensitive Patients)
An Exploratory Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor (AR)-Directed Therapy in Hormono-Sensitive Patients With Metastatic Prostate Cancer (Hormono-sensitive Patients)
Enrollment Status: Completed
Publish Date: April 14, 2022
Intervention Type: Drug, Procedure
Study Phase: Phase 2
View 1 Less Clinical Trial

62 Total Publications

Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review.
Health-related quality of life outcomes in randomized controlled trials in metastatic hormone-sensitive prostate cancer: a systematic review.
Journal: EClinicalMedicine
Published: May 29, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Osanto's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile